Free Newsletter
Register for our Free Newsletters
Analysis, Inspection and Laboratory
Assisted/Independent Living
Clinical and Nursing Equipment
Design and Manufacture of Medical Equipment
Diagnostics Equipment, Monitoring and Test
Education, Training and Professional Services
Health Education and Patient Management
Health Estates Management
Healthcare Support and Information Services
Hygiene and Infection Control
IT and Communications in Healthcare
Medical Device Technology
Research and Development
Safety and Security
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone

CSL Behring signs supply agreement with Canadian Blood Services and Hema-Quebec

CSL Behring : 07 April, 2008  (Company News)
CSL Behring Canada has announced that Canadian Blood Services, and Hema-Quebec, have each awarded the company contracts to supply Helixate FS (Antihemophilic Factor [Recombinant]), Humate P (Antihemophilic factor / von Willebrand Factor Complex [Human], Dried, Pasteurized), Privigen (Immune Globulin Intravenous [Human]), Vivaglobin (Immune Globulin Subcutaneous [Human]) and other plasma-derived products.
The products are used for the treatment of conditions such as haemophilia, von Willebrand Disease, primary immunodeficiency as well as other serious conditions.

The contracts call for CSL Behring to supply the above mentioned life-saving therapies over a period of at least five years, and to provide toll manufacturing services to Canadian Blood Services for the fractionation of Canadian plasma. In addition, with this agreement, CSL Behring will become the main supplier of bleeding disorder treatments in the province of Quebec.

CSL Behring currently maintains a portfolio of 23 different products, which it develops, manufactures, and distributes to the global healthcare community. The company also offers comprehensive consumer support, research and education support, disease awareness campaigns and other initiatives to ensure that patients receive proper diagnoses and treatment interventions.

'We at CSL Behring in Canada are quite pleased with the awards,' said Dr Heinz Neuhaus, general manager of CSL Behring Canada. 'Our company has made significant investments in becoming a reliable partner for both Canadian Blood Services and Hema-Quebec so that we can expand our product offering to Canadian patients in need. It is gratifying to be recognised with a supply agreement that allows us to strengthen even further our commitment to saving and improving lives.'

'CSL Behring continues to grow and expand its capacity to develop, manufacture, and supply a broad array of therapies around the world,' said Paul Perreault, executive vice president of CSL Behring Worldwide Commercial Operations. 'Canada is an extremely important market for us, and we look forward to delivering to Canadians the safe, effective, high-quality medicines for which our company has become known.'

'One of Canadian Blood Services strategic directions for plasma protein products is to broaden its supplier base for commercial products and fractionation services,' said Dr Graham Sher, chief executive officer of Canadian Blood Services. 'This new partnership with CSL allows us to successfully achieve this strategic objective.'

'With its long history of success in the biotherapies industry, CSL Behring Canada has shown it can perform as a trustworthy partner,' said Dr Francine Decary, president and chief executive officer of Hema-Quebec. 'We look forward to initiating what we expect to be a long and productive business relationship with CSL Behring in the supply of important medicines to patients in Quebec.'
Bookmark and Share
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
   © 2012
Netgains Logo